TG Therapeutics Stock News

$70 million funded at closing $70 million funded at closing

Due to the FDA uncertainty, TG Therapeutics shares took a big hit earlier this month. Nevertheless, the stock is showing signs of a rebound going into Fiscal 2022. The upcoming U2 approval for chronic

State of New Jersey Common Pension Fund D boosted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 59.0% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 120,883 shares of the biopharmaceutical companys stock after purchasing an additional 44,854 shares during the period. State of New Jersey Common Pension Fund Ds holdings in []

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / December 16, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, is investigating potential violations of the federal securities laws by TG Therapeutics, Inc. (NASDAQ:TGTX) and certain of its officers and/or directors. On November 30, 2021, TG Therapeutics issued a press release "announc[ing] the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combination of ublituximab and UKONIQ® (umbralisib) ..

NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two data presentations, highlighted data from the UNITY-CLL Phase 3 trial evaluating the combination

NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two data presentations, highlighted data from the UNITY-CLL Phase 3 trial evaluating the combination of ublituximab, the Companys investigational anti-CD20 monoclonal antibody and UKONIQ (umbralisib), the Companys inhibitor of PI3K-delta and CK1-epsilon, (U2), in patients with both treatment naïve and relapsed or refractory chronic lymphocytic leukemia (CLL). Data presentations occurred yesterday evening during the 63 rd American Society of Hematology (ASH) annual meeting and exposition. Presentation highlights are included below.

Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022

Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced four data presentations, including three oral presentations and one poster presentation, evaluating

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced four data presentations, including three oral presentations and one poster presentation, evaluating the combination of ublituximab, the Company’s investigational anti-CD20 monoclonal antibody and UKONIQ® (umbralisib), the Company’s inhibitor of PI3K-delta and CKI-epsilon, (U2), as well as U2-based triple combination therapies, including U2 plus TG’s investigational BTK inhibitor TG-1701. Data presentations occurred this past weekend during the 63 rd American Society of Hematology (ASH) annual meeting and exposition. Presentation highlights are included below.

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 63rd American Society of Hematology (ASH) annual m

The stock price of TG Therapeutics, a commercial stage biopharmaceutical company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases, has seen a large 50% fa

All of these names are down for a reason, but only some of them are down for a reason that's apt to last.

Koshinski Asset Management Inc. bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,000 shares of the biopharmaceutical companys stock, valued at approximately $33,000. A number of other institutional investors and hedge funds have []